Literature DB >> 25623078

Merkel cell carcinoma: histopathologic and prognostic features according to the immunohistochemical expression of Merkel cell polyomavirus large T antigen correlated with viral load.

Valérie Leroux-Kozal1, Nicolas Lévêque2, Véronique Brodard3, Candice Lesage4, Oriane Dudez5, Marc Makeieff6, Lukshe Kanagaratnam7, Marie-Danièle Diebold5.   

Abstract

Merkel cell carcinoma (MCC) is a neuroendocrine skin malignancy frequently associated with Merkel cell polyomavirus (MCPyV), which is suspected to be oncogenic. In a series of MCC patients, we compared clinical, histopathologic, and prognostic features according to the expression of viral large T antigen (LTA) correlated with viral load. We evaluated the LTA expression by immunohistochemistry using CM2B4 antibody and quantified viral load by real-time polymerase chain reaction. We analyzed formalin-fixed, paraffin-embedded (FFPE) tissue samples (n = 36) and corresponding fresh-frozen biopsies when available (n = 12), of the primary tumor and/or metastasis from 24 patients. MCPyV was detected in 88% and 58% of MCC patients by real-time polymerase chain reaction and immunohistochemistry, respectively. The relevance of viral load measurements was demonstrated by the strong consistency of viral load level between FFPE and corresponding frozen tissues as well as between primary tumor and metastases. From FFPE samples, 2 MCC subgroups were distinguished based on a viral load threshold defined by the positivity of CM2B4 immunostaining. In the LTA-negative subgroup with no or low viral load (nonsignificant), tumor cells showed more anisokaryosis (P = .01), and a solar elastosis around the tumor was more frequently observed (P = .03). LTA-positive MCCs with significant viral load had a lower proliferation index (P = .03) and a longer survival of corresponding patients (P = .008). Depending on MCPyV involvement, 2 MCC subgroups can be distinguished on histopathologic criteria, and the CM2B4 antibody is able to differentiate them reliably. Furthermore, the presence of a significant viral load in tumors is predictive of better prognosis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Histopathologic characteristics; Immunohistochemistry; Merkel cell carcinoma; Merkel cell polyomavirus; Polymerase chain reaction; Prognosis

Mesh:

Substances:

Year:  2014        PMID: 25623078     DOI: 10.1016/j.humpath.2014.12.001

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  22 in total

1.  Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection.

Authors:  Ata S Moshiri; Ryan Doumani; Lola Yelistratova; Astrid Blom; Kristina Lachance; Michi M Shinohara; Martha Delaney; Oliver Chang; Susan McArdle; Hannah Thomas; Maryam M Asgari; Meei-Li Huang; Stephen M Schwartz; Paul Nghiem
Journal:  J Invest Dermatol       Date:  2016-11-01       Impact factor: 8.551

Review 2.  Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.

Authors:  Teresa Amaral; Ulrike Leiter; Claus Garbe
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

3.  Detection of the Merkel cell polyomavirus in the neuroendocrine component of combined Merkel cell carcinoma.

Authors:  Thibault Kervarrec; Mahtab Samimi; Pauline Gaboriaud; Tarik Gheit; Agnès Beby-Defaux; Roland Houben; David Schrama; Gaëlle Fromont; Massimo Tommasino; Yannick Le Corre; Eva Hainaut-Wierzbicka; Francois Aubin; Guido Bens; Hervé Maillard; Adeline Furudoï; Patrick Michenet; Antoine Touzé; Serge Guyétant
Journal:  Virchows Arch       Date:  2018-03-28       Impact factor: 4.064

Review 4.  Update on Merkel Cell Carcinoma.

Authors:  Michael T Tetzlaff; Priyadharsini Nagarajan
Journal:  Head Neck Pathol       Date:  2018-03-20

Review 5.  Proceedings of the NASHNP Companion Meeting, March 18th, 2018, Vancouver, BC, Canada: Salivary Neuroendocrine Carcinoma-An Overview of a Rare Disease with an Emphasis on Determining Tumor Origin.

Authors:  Rebecca D Chernock; Eric J Duncavage
Journal:  Head Neck Pathol       Date:  2018-03-20

6.  Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.

Authors:  Paul W Harms; Angela M B Collie; Daniel H Hovelson; Andi K Cani; Monique E Verhaegen; Rajiv M Patel; Douglas R Fullen; Kei Omata; Andrzej A Dlugosz; Scott A Tomlins; Steven D Billings
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

7.  Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay.

Authors:  Lisha Wang; Paul W Harms; Nallasivam Palanisamy; Shannon Carskadon; Xuhong Cao; Javed Siddiqui; Rajiv M Patel; Sylvia Zelenka-Wang; Alison B Durham; Douglas R Fullen; Kelly L Harms; Fengyun Su; Sudhanshu Shukla; Rohit Mehra; Arul M Chinnaiyan
Journal:  Clin Cancer Res       Date:  2017-06-12       Impact factor: 12.531

8.  Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers.

Authors:  Kelly L Harms; Lili Zhao; Bryan Johnson; Xiaoming Wang; Shannon Carskadon; Nallasivam Palanisamy; Daniel R Rhodes; Rahul Mannan; Josh N Vo; Jae Eun Choi; May P Chan; Douglas R Fullen; Rajiv M Patel; Javed Siddiqui; Vincent T Ma; Steven Hrycaj; Scott A McLean; Tasha M Hughes; Christopher K Bichakjian; Scott A Tomlins; Paul W Harms
Journal:  Clin Cancer Res       Date:  2021-02-05       Impact factor: 12.531

9.  ALK is frequently phosphorylated in Merkel cell carcinoma and associates with longer survival.

Authors:  Jenni Jaatinen; Tuukka Veija; Marko Salmikangas; Tom Böhling; Harri Sihto; Virve Koljonen
Journal:  PLoS One       Date:  2021-05-24       Impact factor: 3.240

10.  Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications.

Authors:  Philip R Cohen; Razelle Kurzrock
Journal:  Dermatol Ther (Heidelb)       Date:  2015-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.